COMMUNIQUÉS West-GlobeNewswire

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
20/03/2025
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R [...]
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
20/03/2025
REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
20/03/2025
Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes [...]
IBA reports solid Full Year 2024 results
20/03/2025
Read the entire full year 2024 results press release here Louvain-la-Neuve, Belgium, 20 March 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated [...]
IBA publie des résultats solides pour l'année 2024
20/03/2025
Cliquez ici pour lire l'intégralité du communiqué de presse des résultats de l'exercice 2024 Louvain-La-Neuve, Belgique, jeudi 20 mars 2025 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’ [...]
Press release: Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation
20/03/2025
Sequana Medical to Sponsor Liver Connect, 5 th Annual Conference of Chronic Liver Disease Foundation Ghent, Belgium – 20 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , a [...]
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
20/03/2025
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition [...]
Communiqué de presse : Sanofi va acquérir l’anticorps bispécifique de Dren Bio – un « engageur » des cellules myéloïdes pour la déplétion profonde des lymphocytes B –, et étoffe son portefeuille en immunologie
20/03/2025
Sanofi va acquérir l’anticorps bispécifique de Dren Bio – un « engageur » des cellules myéloïdes pour la déplétion profonde des lymphocytes B –, et étoffe son portefeuille en immunologie L’agent de déplétion profonde [...]
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
20/03/2025
Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 million including sale of Priority Review Voucher 1 , successful private placement and [...]
Valneva publie ses résultats financiers 2024 et fait un point sur son activité et ses perspectives financières
20/03/2025
Atteinte des objectifs 2024 de croissance des ventes (+13% vs 2023) et de chiffre d’affaires (+10% vs 2023) Solide position de trésorerie de 168,3 millions d’euros à fin 2024 incluant les produits de la vente du bon de [...]
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
20/03/2025
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today [...]
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
20/03/2025
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of [...]
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
20/03/2025
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10 ‑ million ‑ patient market Acquisition advances Paratek’s vision to become a [...]
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
20/03/2025
— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO ® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of [...]
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
20/03/2025
TORONTO, ONTARIO, March 19, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“ COSCIENS ” or the “ Company ”), a life science company which develops and commercializes a diversified portfolio [...]
Hyku Biosciences Appoints Keith Wilcoxen, PhD, as Chief Scientific Officer
19/03/2025
BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Hyku Biosciences, a pioneer in precision medicine, today announced the appointment of Keith Wilcoxen, PhD, as Chief Scientific Officer. Dr. Wilcoxen has more than 25 [...]
Pacific Health Care Organization, Inc. Reports its 2024 Year-End Financial Results
19/03/2025
Irvine, CA, March 19, 2025 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “Commission”) its annual report on Form [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/03/2025
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
Galecto Reports Full-Year 2024 Financial Results
19/03/2025
Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge [...]

Pages